Zolpidem

StimScience Hires Former Fitbit Executive Tim Rosa as Chief Executive Officer to Scale its Somnee Sleep and Neuroscience Wearable Business

Retrieved on: 
Wednesday, March 6, 2024

Somnee – the first personalized, smart sleep headband that utilizes non-invasive, closed-loop neurostimulation for longer, higher quality sleep – today announced the appointment of Tim Rosa as its Chief Executive Officer (CEO).

Key Points: 
  • Somnee – the first personalized, smart sleep headband that utilizes non-invasive, closed-loop neurostimulation for longer, higher quality sleep – today announced the appointment of Tim Rosa as its Chief Executive Officer (CEO).
  • “Wearables have done a great job educating consumers on their general sleep stage trends and insights.
  • We backed Somnee because the team had every component needed to bring forward clinical-grade consumer technology to change the face of sleep.
  • As the former Chief Marketing Officer (CMO) at Fitbit, he was pivotal in establishing the connected health and fitness wearables category.

MotherToBaby Launches Spanish-Language Digital Health Website to Reach Underserved Latinx Communities in the U.S. & Canada

Retrieved on: 
Wednesday, January 10, 2024

BRENTWOOD, Tenn., Jan. 10, 2024 /PRNewswire-PRWeb/ -- ¿Hablas español? ¡Sí! In time for January's Birth Defects Awareness Month, MotherToBaby is proud to announce the launch of its fully bilingual (English/Spanish) website. It's the first of its kind for housing an extensive bilingual library of fact sheets on everything from alcohol to zolpidem during pregnancy and breastfeeding as well as connecting bilingual experts with parents and healthcare providers.

Key Points: 
  • In time for January's Birth Defects Awareness Month, MotherToBaby is proud to announce the launch of its fully bilingual ( English / Spanish ) website.
  • "No matter what the language they speak is, we want everyone to have access to the best, expert health information possible."
  • The now fully bilingual website is designed to fill the gap in the disparities of health education information for pregnant and breastfeeding individuals who are Spanish-speakers.
  • MotherToBaby wants to improve birth outcomes in the Latinx community by giving improved access to language-appropriate resources to families and health professionals.

How can I get some sleep? Which treatments actually work?

Retrieved on: 
Thursday, October 26, 2023

This article is the next in The Conversation’s six-part series on insomnia, which charts the rise of insomnia during industrialisation to sleep apps today.

Key Points: 
  • This article is the next in The Conversation’s six-part series on insomnia, which charts the rise of insomnia during industrialisation to sleep apps today.
  • Do these sleep problems make you feel fatigued, strung-out, or exhausted during the day?
  • Read more:
    A short history of insomnia and how we became obsessed with sleep

What not to do


These probably won’t help:
spending more time in bed often results in more time spent awake in bed, which can make insomnia patterns worse
drinking coffee and taking naps might help get you through the day. But caffeine stays in the system for many hours, and can disrupt our sleep if you drink too much of it, especially after about 2pm. If naps last for more than 30 minutes, or occur after about 4pm, this can reduce your “sleep debt”, and can make it more difficult to fall asleep in the evening
drinking alcohol might help you fall asleep quicker, but can cause more frequent awakenings, change how long you sleep, change the time spent in different “stages” of sleep, and reduce the overall quality of sleep. Therefore, it is not recommended as a sleep aid.

Read more:
Why do I fall asleep on the sofa but am wide awake when I get to bed?

What to do next?

  • So, the next stage is a type of non-drug therapy known as cognitive behavioural therapy for insomnia (or CBTi for short).
  • It involves education about sleep, and offers psychological and behavioural treatments that address the underlying causes of long-term insomnia.
  • Some GPs are trained to offer CBTi, but it’s more usual for specialist sleep psychologists to offer it.
  • But many psychologists will also charge a gap fee above the Medicare subsidy, making access to CBTi a challenge for some.

What if that doesn’t work?

  • Some lifestyle and work factors, such as shift-work, might also require management by a specialist sleep doctor.
  • Read more:
    Counting the wrong sheep: why trouble sleeping is about more than just individual lifestyles and habits

What about sleeping pills?

  • Sleeping pills are not the recommended first-line way to manage insomnia.
  • Read more:
    Some reasons why you should avoid sleeping pills

Are there new treatments? How about medicinal cannabis?


Two newer drugs, known as “orexin receptor antagonists”, are available in Australia (suvorexant and lemborexant). These block the wake-promoting pathways in the brain. Early data suggests they are effective in improving sleep, and have lower risk of potential side-effects, tolerance and dependence compared with earlier medicines. However, we don’t know if they work or are safe over the long term.

  • Medicinal cannabis has only in recent years been studied as a treatment for insomnia.
  • In an Australian survey, more than half of people using medicinal cannabis said they used it to treat insomnia.

What now?

  • Your GP can help identify and manage these.
  • Your GP can also help you access other treatments if your insomnia is more long term.
  • Dr Sweetman reports previous research funding and/or consultancy work for; the National Health and Medical Research Council, The Hospital Research Foundation, Flinders University, Flinders Foundation, ResMed, Philips, Cerebra, Re-Time, and Australian Doctor.
  • Nicole Grivell is involved in the Australasian Sleep Association as a co-chair of the Primary Care Council and as a member of the Conference Committee.
  • She has previously received PhD funding from the Flinders Foundation in the form of a Nick Antic Sleep Research PhD Scholarship.

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

Retrieved on: 
Wednesday, August 23, 2023

NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer.

Key Points: 
  • NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer.
  • His deep understanding of drug development and his strategic insights will be invaluable as Tiziana continues to advance its pipeline.
  • Commenting on his new role, William A. Clementi said, "I am excited to join Tiziana Life Sciences and contribute to the advancement of its innovative therapeutic candidates.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, expressed his enthusiasm about the appointment, stating, "We are delighted to welcome William to Tiziana as our Chief Development Officer.

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Retrieved on: 
Thursday, July 27, 2023

Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team.

Key Points: 
  • Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team.
  • In 1991 Dr. Clementi established a regulatory consulting company, Clementi & Associates, Ltd. (dba as Clementi Ltd).
  • "We are delighted to welcome William Clementi to OKYO Pharma as our new Chief Operating Officer.
  • Dr. Clementi's appointment comes at a crucial time for OKYO Pharma, with significant milestones on the horizon.

Oomph Body's Natural Sleep Aids Beat Pharmaceutical Alternatives

Retrieved on: 
Thursday, June 29, 2023

FORT LAUDERDALE, Fla., June 29, 2023 /PRNewswire/ -- Insomnia is a common struggle. As much as 33% of adults struggle with significant sleep deprivation, while one in 10 adults is considered to have chronic insomnia as a medical condition.

Key Points: 
  • But Sleep Foundation reports nearly twenty different potential side effects that come from taking sleep medications, including nausea, dizziness, and even uncontrollable shaking.
  • This struggle between insomnia and the side effects of sleep medications is what led the health and wellness brand Oomph Body to develop its Lights Out and Deep Sleep aminos products.
  • Both dietary supplements use natural ingredients like GABA and Choline Bitartrate to help improve quality of sleep and parasympathetic nervous system function, respectively, leading to a better night's sleep.
  • As is the case with all of Oomph Body's supplements, Deep Sleep and Lights Out offer the brand's customers a clean, natural alternative to harmful pharmaceutical-grade products.

New Research Shows Sleep Reset Is First & Only Digital Sleep Solution Clinically Proven to Increase Total Sleep Time by Over One Hour for Short Sleepers

Retrieved on: 
Tuesday, June 6, 2023

The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.

Key Points: 
  • The University of Arizona's Sleep and Health Research Program led the study which shows Sleep Reset's ability to increase sleep time, addressing a significant concern for many healthcare professionals.
  • "Remarkably, data from Sleep Reset reveals that this program has the potential to significantly extend the duration of their sleep.
  • Many popular sleep solutions like Trazadone, Benadryl and Melatonin don't even have the clinical evidence to increase total sleep time much at all.
  • Ambien and Lunesta are known to increase sleep time by around 30 minutes, but that's much less than what we've seen from Sleep Reset.

Challenging the FDA's authority isn't new – the agency's history shows what's at stake when drug regulation is in limbo

Retrieved on: 
Wednesday, April 26, 2023

The agency has frequently come under fire for its drug approval decisions, but attacks on its decision-making process and science itself have increased during the COVID-19 pandemic.

Key Points: 
  • The agency has frequently come under fire for its drug approval decisions, but attacks on its decision-making process and science itself have increased during the COVID-19 pandemic.
  • Recent challenges to the FDA’s authority have emerged in the context of reproductive rights.
  • I am a legal scholar whose research focuses in part on the law and ethics of the FDA’s drug approval process.
  • Examining the FDA’s history reveals the unprecedented nature of the current challenges to the agency’s authority.

Events shaping FDA’s focus on safety

    • In its early years, the FDA focused primarily on balancing the competing goals of consumer safety with access to experimental treatments.
    • For instance, at the turn of the 20th century, Congress passed the Biologics Control Act of 1902, providing the federal government the authority to regulate vaccines.
    • This act marked the beginning of modern drug regulations and the birth of the FDA as a regulatory agency.

FDA’s turn toward expanding access

    • During the 1970s, questions about the limits of safety versus an individual’s right to access arose when cancer patients who wanted access to an unapproved drug derived from apricots, Laetrile, sued the FDA.
    • The 1980s, however, marks the FDA’s shift toward increasing access following reports of an emerging disease – AIDS – which primarily affected gay men.
    • After massive protests, Dr. Anthony Fauci, then director of the National Institute of Allergy and Infectious Diseases, proposed a parallel track program allowing eligible patients access to unapproved experimental treatments.

Future of the FDA

    • While the FDA approves drugs for consumer use, it does not regulate the general practice of medicine.
    • Doctors can prescribe FDA-approved drugs off-label, meaning they could prescribe a drug with a different dose, in a different way or for a different use than what the FDA has approved it for.
    • The mifepristone case has broad implications for the FDA’s future and could have devastating effects on health in the U.S. Due in part to FDA involvement, public health interventions have led to a 62% increase in life expectancy in the 20th century.

Global Zolpidem (CAS 82626-48-0) Market Analysis Report 2022: Trends and Developments, Prices, Patents, Manufacturing Methods, Major Players, Applications, Key Downstream Industries - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022

The "Zolpidem (CAS 82626-48-0) Global Market Research Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Zolpidem (CAS 82626-48-0) Global Market Research Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Zolpidem.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Zolpidem global market report key points:

ZappyNow Achieved 2021 Global 500 Best Business Model Award

Retrieved on: 
Tuesday, June 28, 2022

ZappyNow (Zappy Tech Group Limited), won the 2021 Global 500 Best Business Model Award.

Key Points: 
  • ZappyNow (Zappy Tech Group Limited), won the 2021 Global 500 Best Business Model Award.
  • ZappyNow is a platform that connects merchants, businesses, and users.
  • Since its launch on July 1, 2019, ZappyNow successfully attracted more than 25 million registered users.
  • As of September 2021, ZappyNow has created 9 million of job opportunities globally.